{'fraction_non_alphanumeric': 0.03067484662576687, 'fraction_numerical': 0.01687116564417178, 'mean_word_length': 5.595959595959596, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Patterns of Pharmaceutical Industry Marketing to Physicians for Direct-Acting Antivirals, 2013 Through 2019

Direct-acting antivirals (DAAs) are novel drugs that have changed the treatment landscape of hepatitis C. Novel brand-name medications, like DAAs, are highly priced, bringing financial burden to patients and health systems.1 Physicians’ uptake after approval is key to commercial success of these medications, with uptake associated with peer influence and their relationship with pharmaceutical marketing.2,3 However, little is known about patterns of pharmaceutical marketing for DAAs. Thus, in this study, we aim to fill this knowledge gap.